Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 151

Results For "report"

1824 News Found

AsterDM Healthcare Q3FY22 PAT at Rs 148.34 cr.
News | February 08, 2022

AsterDM Healthcare Q3FY22 PAT at Rs 148.34 cr.

Aster DM Healthcare has reported consolidated financial results for the period ended December 31, 2021


Suven Pharma Q3FY22 PAT at Rs. 160.06 crore
News | February 08, 2022

Suven Pharma Q3FY22 PAT at Rs. 160.06 crore

Suven Pharmaceuticals has reported consolidated financial results for the period ended December 31, 2021.


Venus Remedies join AMR alliance to combat global health threat
Biotech | February 07, 2022

Venus Remedies join AMR alliance to combat global health threat

The antimicrobial resistance alliance recently released its third Progress Report, reflecting on collective achievements from the life sciences industry


Mangalam Drugs and Organics Q3FY22 PAT at Rs. 4.02 crore
News | February 05, 2022

Mangalam Drugs and Organics Q3FY22 PAT at Rs. 4.02 crore

Mangalam Drugs and Organics Limited has reported standalone financial results for the period ended December 31, 2021


Sun Pharma Advanced Research Company Q3FY22 loss at Rs. 15.84 crore
News | February 05, 2022

Sun Pharma Advanced Research Company Q3FY22 loss at Rs. 15.84 crore

Sun Pharma Advanced Research Company has reported standalone financial results for the period ended December 31, 2021


IOL Chemicals and Pharmaceuticals Q3FY22 PAT at Rs. 40.07 crore
News | February 05, 2022

IOL Chemicals and Pharmaceuticals Q3FY22 PAT at Rs. 40.07 crore

IOL Chemicals and Pharmaceuticals has reported standalone financial results for the period ended December 31, 2021


Dishman Carbogen Amcis Q3FY22 PAT at Rs. 35.38 crore
News | February 05, 2022

Dishman Carbogen Amcis Q3FY22 PAT at Rs. 35.38 crore

Dishman Carbogen Amcis has reported consolidated financial results for the period ended December 31, 2021


Lupin Q3FY22 PAT at Rs 545.52 cr.
News | February 04, 2022

Lupin Q3FY22 PAT at Rs 545.52 cr.

Lupin has reported consolidated financial results for the period ended December 31, 2021


Pfizer Q3FY22 PAT at Rs 143.91 crore
News | February 04, 2022

Pfizer Q3FY22 PAT at Rs 143.91 crore

The company has reported standalone financial results for the period ended December 31, 2021.


Caplin Point Q3FY22 PAT at Rs 74.95 cr.
News | February 03, 2022

Caplin Point Q3FY22 PAT at Rs 74.95 cr.

Caplin Point Laboratories has reported consolidated financial results for the period ended December 31, 2021.